Sweden's Devyser Q2 prelim sales weaken on distributor inventory build-up

Overview

• Sweden diagnostics kit maker's preliminary Q2 sales weakened due to distributor inventory build-up

• Company expects softer sales growth to main distributor for rest of 2026

• Liquidity and cash flow forecast remain satisfactory despite weaker sales

Outlook

• Devyser expects sales to its largest distributor to grow at a softer rate for rest of 2026

• Company anticipates sales to largest distributor to normalize from 2027 onwards

Result Drivers

• DISTRIBUTOR INVENTORY BUILD-UP - Co said Q2 sales were negatively impacted by inventory build-up at its largest distributor, reducing purchasing needs during the period

• DIRECT AND OTHER MARKETS - Co said direct markets and other distributor markets continued to deliver positive sales growth

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Devyser Diagnostics AB is SEK164.00, about 97.8% above its July 2 closing price of SEK82.90

• The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 25 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact .